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Objectives
At the conclusion of this session, the participant will 
be able to:
 Describe the evidence for opioid prescribing risk mitigation 
strategies.
 Review different opioid prescribing risk mitigation strategies.
 Summarize steps that clinicians can take when concerning 
information is discovered through prescription drug 
monitoring program checks and urine drug testing.
 Evaluate factors that increase risk for opioid overdose and 
determine when co-prescribing naloxone would be beneficial.
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Evidence
• Most fatal prescription opioid overdoses associated with* 
– high total daily opioid dosages and/or
– receiving opioids from multiple sources
PDMP provides information on both these risk factors
• Urine drug tests can provide information about drug use 
that is not reported by the patient
• Naloxone distribution associated with decreased opioid 
overdose deaths at the community level** 
*Gwira Baumblatt et al. High-risk use by patients prescribed opioids for pain and its role in overdose deaths.  JAMA 
Intern Med 2014;174:796–801
**Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal 
naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013;346:f174
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Gwira Baumblatt et al. High Risk Use by Patients Prescribed Opioids for Pain and  its Role in Overdose Deaths. 
JAMA Intern Med 2014; 174: 796-801.
Check PDMP for high dosages 
and dangerous combinations
• Clinicians should review the patient’s history of controlled 
substance prescriptions using state PDMP data to 
determine whether the patient is receiving opioid dosages 
or dangerous combinations that put him/her at high risk 
for overdose. 
• Clinicians should review PDMP data when starting opioid 
therapy for chronic pain and periodically during opioid 
therapy for chronic pain, ranging from every prescription to 
every 3 months.
(Recommendation category A: Evidence type: 4)
If you find concerning information in the PDMP, take action to 
improve patient safety 
• Discuss safety concerns including increased overdose risk
• For patients receiving high total opioid dosages 
– consider tapering to a safer dosage
– consider offering naloxone
• Consider opioid use disorder and discuss concerns
• If patients are taking benzodiazepines with opioids
– communicate with others managing the patient 
– weigh patient goals, needs, and risks
• Do not dismiss patients from care—use the opportunity to provide potentially 
lifesaving information and interventions
Example Fact Sheet
EXAMPLE FACT SHEET
Test urine for prescribed
opioids and other drugs
• When prescribing opioids for chronic pain, clinicians should use urine drug 
testing before starting opioid therapy and consider urine drug testing at least 
annually to assess for prescribed medications as well as other controlled 
prescription drugs and illicit drugs.
(Recommendation category B: Evidence type: 4)
Initial urine drug testing
• Start with an immunoassay panel for 
– prescribed opioids
– other controlled substances 
– illicit drugs that increase risk for overdose 
• Do not test for drugs that would not affect patient management 
• Be familiar with testing panels used in your practice and how to interpret 
results 
Discussing urine drug testing with patients
• Explain that drug testing is used to improve safety 
• Explain expected results 
– presence of prescribed medication
– absence of unreported drugs, including illicit drugs
• Ask about use of prescribed and other drugs and if there might be 
unexpected results 
• Provide an opportunity for patients to disclose changes in their use of 
prescribed opioids or other drugs
Confirming unexpected results
• Discuss unexpected results with 
– Local laboratory or toxicologist 
– Patient
• If unexpected results are not explained, confirm with a selective test such as 
gas or liquid chromatography/mass spectrometry
Use unexpected results to improve patient safety
• Do not dismiss patients from care based on a urine drug test result
• Consider as appropriate
– Change in pain management strategy 
– Tapering and discontinuing opioids 
– More frequent re-evaluation  
– Offering naloxone 
– Treatment for substance use disorder
Evaluate and address risks for 
opioid-related harms
• Before starting and periodically during continuation of opioid therapy, clinicians 
should evaluate risk factors for opioid-related harms. 
• Clinicians should incorporate into the management plan strategies to mitigate 
risk, including considering offering naloxone when factors that increase risk for 
opioid overdose, such as history of overdose, history of substance use disorder, 
higher opioid dosages (>50 MME/day), or concurrent benzodiazepine use, are 
present. 
(Recommendation category A: Evidence type: 4)
How to prescribe naloxone
• Resources for prescribing naloxone 
available at 
http://prescribetoprevent.org
– Sample prescribing directions
– Information for patients and their 
family or household members
– Information for pharmacists
• Naloxone co-prescribing can be 
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Risk mitigation strategies: case
 Beth, a 65 year old woman with rheumatoid arthritis and 
mild joint deformity, who is transferring care due to 
insurance changes
 Adherent to disease-modifying RA treatment that has 
been partially effective
 Prescribed #60 oxycodone/acetaminophen 5/325 mg 
each month for 10 years and denies adverse effects or 
symptoms of opioid use disorder - total opioid dose 15 
mg MED
 Has no prior urine testing, prescription drug monitoring 
program checks, or controlled substances agreement
Risk mitigation strategy outline
 Prescription drug monitoring programs (PDMP)
 Urine toxicology testing
 Controlled substances agreements
 Apply these strategies in a lower risk case
Strategy: prescription drug 
monitoring program
 Can identify patients with high risk prescribing
 From a state perspective, can identify very high risk patients 
who may require specific interventions
 States that require PDMP checks prior to prescribing show 
reduction in patients with multiple prescribers
 Some evidence that physicians who have access to PDMP 
data prior to prescribing may prescribe more opioids
 Results may be difficult to interpret
Strategy: prescription drug 
monitoring program
 Case:
 Two prescriptions in the past year from a dentist for 
hydrocodone/acetaminophen 5/325 mg (#10)
 One prescription from an emergency department visit after an 
ankle sprain (oxycodone 5 mg #12)
 Opportunity to discuss: 
 Risks of co-prescribing of opioids
 Potential toxicity of additional acetaminophen
 Importance of patient reporting outside prescribing 
 Document discussion in medical record
Strategy: urine toxicology testing
 Can assist in safety monitoring and diagnosing substance 
use disorders
 Complex to interpret
 Screening tests vary in sensitivity and specificity
 False positive and false negative results are common
 Patterns of results more important than a single test
 Best used as a trigger for closer follow up and repeat tests
Strategy: urine toxicology testing -
Pitfalls
 Opioids
 False positive: poppy seeds
 False negative: oxycodone on opioid screens – need 
specific test
 Amphetamine/methamphetamine
 False positive: bupropion, trazodone, decongestants, etc
 Benzodiazepine
 False positive: sertraline
 False negative: clonazepam, lorazepam
Strategy: urine toxicology testing
 Case
 Urine toxicology negative for prescribed oxycodone
 Specific test also negative
 Patient reports taking medication prior to activity, not every day
 Low dose, intermittent use can result in negative tests
 Urine toxicology testing can be useful for safely 
monitoring and addiction assessment, but many pitfalls
 Discuss unexpected results with the lab you are using, as 
test characteristics vary
Strategy: controlled substances 
agreement
 Common approach to informing patients of opioid risks 
and clinic policies, and anticipating potential problems
 Present rationale as providing informed consent for all 
patients regarding a potentially risky treatment
 Emphasize no dose escalation without prior consultation 
– “let me be the doctor”
 Can be coupled with assessment of patient side effects, 
ranging from sedation to constipation to depression to 
loss of control
Strategy: controlled substances 
agreement
 Case:
 In the last year or two, the patient has noted less energy 
and more difficulty concentrating later in the day after 
taking opioids
 Almost fell after taking two tablets on an especially active 
day
 Expresses interest in additional non-medication 
approaches
Risk mitigation strategies –
conclusions
 Important components for monitoring safety of long term 
opioid prescribing
 Prescription drug monitoring program  and urine 
toxicology checks can be useful, but their limitations 
must be understood
 Patient education about the risks of prescribing and 
clinic policies provides an opportunity to avoid problems 
and reconsider opioid prescribing  
Risk mitigation strategies: 
Prescription Drug Monitoring Programs 
(PDMPs), urine drug testing, and 
naloxone




Safe management of high dose 
opioid case
 Mr Thomas is a 46 yr old man with low back pain 
persisting for 8 yrs, and initiated when he was injured at 
work.  
 Apart from back pain, he has no other health issues and 
takes no medications other than opioids.  
 He has not worked since the injury.  
 He has some residual low back and left leg pain, and 
evidence on MRI of slight encroachment of L4 nerve root 
due to foraminal stenosis. 
Safe management of high dose 
opioid case
 He is not considered a suitable candidate for surgery.  
 Epidural steroid injections have provided some relief in 
the past but he is not interested in receiving any more 
injections because “it doesn’t last long enough to be 
worth it”.  
 He has tried physical therapy, but feels that it has not 
helped and he is not willing to try more.  
 He takes 30 mg methadone 3 times daily, plus 
oxycodone IR 10 mg, up to 6 daily
 Total opioid dose 1170mg MMD 
Safe management of high dose 
opioid case
 He has always been a compliant patient, although he has not 
had a UDT since early in the course of treatment, the PDMP 
has never been checked, and there is no opioid agreement 
on file.  
 The provider recently learned about the CDC Guideline for 
Prescribing Opioids for Chronic Pain, and when looking at the 
CDC’s recommendations, realized that his patient was on 
opioid doses that were no longer considered safe.  
 What must the provider do now to improve the safety of the 
current regime?
First
 Speak to the patient and his family about the new information 
that has emerged about serious safety considerations related 
to high dose opioids.  
 Explain that new measures need to be taken in order to 
comply with today’s standard of care.   
 Explain that one measure will be to gradually taper the opioid 
to a safer dose, or to discontinuation.  
 Explain that the taper can be done slowly so that there is no 
unpleasant withdrawal, that most people feel better on a 
lower dose, and that pain relief is not compromised. 
First
 Prescribe naloxone and 
explain to patient and 
family why this has 
become necessary, and 
how and when to use it.   
 If the patient is upset, 
wait until next visit to start 
the taper.
Second
 Evaluate for comorbidities that could increase risk
Comorbidities Recommended actions
Depression or anxiety Counseling and possible medication
PTSD or history of abuse/trauma Consider psychiatric referral
Poor sleep Consider sleep study, teach sleep hygiene
Sleep apnea Consider formal assessment and treatment
Obesity Consider nutritional consult
Constipation Treat with diet, stool softener and gentle laxative
Risk of misuse or abuse Get baseline from opioid risk screener
Cognitive impairment Screen for reaction times, discuss driving risks
Dementia Protect against falls
Medication issues CNS depressants, anticholinergics
Third
 Get a baseline UDT
 Check the PDMP
 Write up a goal directed opioid agreement and explain 
why it is needed
Fourth
 Explain tapering options:
1) Slow taper starting with either long acting or short acting (not 
both)
2) Rapid taper with suboxone induction (not option if tapering 
methadone)
3) Adjuncts for depression or anxiety during taper (eg small 
dose of TCA)
4) If also on a benzodiazepine, choose between opioid and 
benzodiazepine
Fifth
Depending on results of UDT, PDMP and medical evaluation, 
decide upon:
 speed of taper
 possible need for immediate discontinuation (rare, only if needed for 
safety)
 future frequency of provision of prescriptions
 UDT schedule
 PDMP review schedule
 need for additional providers (eg psychology/psychiatry, PT, group 
therapy)
Fifth
 If addiction is diagnosed, refer for addiction 
treatment and do not prescribe opioids for pain  
once addiction treatment is started.  Continue 
treating pain using non-opioid modalities. 
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